Text Size

Studying Gene Expression in Samples From Patients With Rhabdoid Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01553175
First received: March 10, 2012
Last updated: March 17, 2012
Last verified: March 2012
History of Changes

March 10, 2012
March 17, 2012
March 2012
May 2012   (final data collection date for primary outcome measure)
  • Absence or presence BRG1 and BRM expression in rhabdoid tumors [ Designated as safety issue: No ]
  • Mechanism of suppression of BRG1 and BRM genes [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01553175 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.

OBJECTIVES:

  • To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
  • To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
  • To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.
  • To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.
  • To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.

OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Brain and Central Nervous System Tumors
  • Kidney Cancer
  • Genetic: DNA analysis
  • Genetic: gene expression analysis
  • Genetic: mutation analysis
  • Genetic: protein expression analysis
  • Other: immunohistochemistry staining method
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
25
Not Provided
May 2012   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Tumor samples from patients diagnosed with rhabdoid tumors
  • Matched frozen tumor tissue from BRG1-negative tumors (preferred) or matched genomic DNA from tumors, 100 ng per tumor from BRG1-negative tumors
  • Any source of DNA from BRG1-negative tumors (tumors, blood, etc.)
  • Matched frozen tumor tissue from BRM-negative tumors to confirm that BRM is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01553175
CDR0000728521, COG-AREN12B5
Not Provided
Peter C. Adamson, Children's Oncology Group - Group Chair Office
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: David Reisman, MD, PhD University of Florida
National Cancer Institute (NCI)
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP